0      0

AM21-52: Financial Challenges in the Age of Cell and Gene Therapies

Oct 19, 2021 7:15pm ‐ Oct 19, 2021 8:15pm

Credits: None available.


Cell and gene therapies offer unprecedented hope to a growing number of patients. In the treatment of refractory/relapsed malignancy, a single dose may be lifesaving. Payment models may threaten the commercial viability of these therapies. Incremental cost effectiveness analyses have supported manufacturers’ high retail prices for these agents. Payers, on the other hand, are hesitant to pay for such an expensive agent when the benefit may be enjoyed by a competitor to insurance churn. Patients are unlikely to be able to cover such high-cost therapies out of pocket. Operational challenges are also a threat to successful implementation of these therapies. Commercialization of these agents has exposed uncompensated effort throughout the procurement cycle. This session aims to highlight different perspectives on financial challenges of cell and gene therapies and prompt the investigation of innovative solutions.




Credits: None available.

You must be logged in and own this session in order to post comments.